Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: allopurinol

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

Allopurinol and Chronic Kidney Disease

From the College  |  September 23, 2024

Allopurinol for Gout an Unlikely Contributor to Kidney Disease

Reuters Staff  |  October 8, 2018

NEW YORK (Reuters Health)—Allopurinol does not appear to contribute to decline in kidney function and may actually protect renal function in patients with gout, according to a large population-based study. Gout affects around 4% of Americans and often occurs alongside chronic kidney disease (CKD), Dr. Tuhina Neogi from Boston University School of Medicine and colleagues…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Allopurinolchronic kidney diseaseGoutkidney

FDA Approves Lesinurad + Allopurinol

Michele B. Kaufman, PharmD, BCGP  |  September 19, 2017

Duzallo, a combination of lesinurad and allopurinol, was approved by the FDA in August to treat hyperuricemia associated with gout…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:AllopurinolDuzalloFDAFood and Drug AdministrationGouthyperuricemialesinuradU.S. Food and Drug Administration

Allopurinol Appears More Renoprotective than Febuxostat in Older Adults

Reuters Staff  |  July 20, 2017

NEW YORK (Reuters Health)—The renal protective effect of allopurinol appears to differ from that of febuxostat in the elderly, according to new research. The study, of a nationally representative sample of Medicare patients, showed that allopurinol was associated with a greater reduction in the risk of incident kidney disease, report the authors online July 13…

Filed under:ConditionsDrug Updates Tagged with:AllopurinolFebuxostatkidney diseaseMedicare patientsrenal protective effect

Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient

Arthritis & Rheumatology  |  December 29, 2016

Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:AllopurinolArthritis & RheumatologyGoutlesinuradResearchUric acid

Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions

Deborah Levenson  |  September 8, 2016

Be careful when prescribing allo­purinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have an increased…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:AllopurinolGoutoutcomepatient carerheumatologistriskskin reactionTreatmentUric acid

The 5 Ms: A Simple Framework to Care for Older Patients

Samantha C. Shapiro, MD  |  December 5, 2024

WASHINGTON, D.C.—For the first time in U.S. history, older adults are projected to outnumber children by 2034, and their care poses unique challenges to the rheumatologist.1 Normal physiologic changes of aging include but aren’t limited to falling renal function, changes in pharmacokinetics and bone density loss. At the ACR Convergence 2024 Review Course, Namrata Singh,…

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024elder care

Urate-Lowering Therapy in the Treatment of Patients with Chronic Kidney Disease

Summarized from The New England Journal of Medicine  |  December 2, 2024

In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Gout Resource Center

Better Education on Gout

Mary Beth Nierengarten  |  November 22, 2024

Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 goutadherenceFollow-UpGoutpatient educationRemissionserum urate levels

Your Gout Guide for ACR Convergence 2024: Dr. Lisa Stamp

Glen Rodman  |  September 25, 2024

Lisa Stamp, MBChB, PhD, is here to help the busy clinician by curating a collection of the most significant and notable abstracts in gout research to be presented at ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisGuidanceMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 goutGout

  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences